 |
Photo = Samsung Biologics |
[Alpha Biz= Kim Jisun] A South Korean court has partially restricted a planned full-scale strike by the labor union at Samsung Biologics.
On April 23, the Incheon District Court granted in part the company’s injunction request against its union, ruling that workers must not disrupt critical processes related to preventing contamination or deterioration of cell cultures. The court also barred any actions that could interfere with employees performing such essential tasks.
Specifically, strike actions were prohibited in three areas: concentration and buffer exchange, bulk filling, and related buffer production and supply. However, the court rejected the injunction for other processes, including cell culture and purification.
Samsung Biologics said it has received the ruling and filed an immediate appeal on the portions not granted.
The union had previously voted in favor of a strike, with 95.52% approval, and plans to begin collective action on April 22, followed by a full strike on May 1 if negotiations fail. The union represents about 3,689 members, roughly 75% of the workforce.
Key issues include wages and bonuses. The union is demanding a 14% base salary increase and performance bonuses equivalent to 20% of operating profit, along with additional incentives. The company has proposed a 6.2% wage increase and expanded allowances, while maintaining its existing bonus framework.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
